Walvax Biotechnology released its 2026 interim report. Total operating revenue was 834 million yuan, down 27.72% from the same period last year. Net profit attributable to the parent company was 54.192 million yuan. Net cash inflow from operating activities was 174 million yuan. The asset-liability ratio was 30.18%, gross margin was 68.79%, return on equity was 0.78%, and diluted earnings per share was 0.03 yuan. The company had 131,000 shareholders, and the top ten shareholders held 14.54% of total share capital.
Walvax BioTechRevenue down 27.72% YoY, net profit only 54.192 million yuan, indicating weak financial performance.
